Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $119.6 million.

  • Catalyst Pharmaceuticals' Accumulated Expenses rose 2750.34% to $119.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.6 million, marking a year-over-year increase of 2750.34%. This contributed to the annual value of $104.1 million for FY2024, which is 6988.48% up from last year.
  • Catalyst Pharmaceuticals' Accumulated Expenses amounted to $119.6 million in Q3 2025, which was up 2750.34% from $107.5 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Accumulated Expenses peaked at $119.6 million during Q3 2025, and registered a low of $11.9 million during Q1 2021.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Accumulated Expenses value was $53.3 million (recorded in 2023), while the average stood at $57.7 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Accumulated Expenses plummeted by 2709.33% in 2021 and then surged by 19955.62% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Accumulated Expenses (Quarter) stood at $24.3 million in 2021, then surged by 120.68% to $53.6 million in 2022, then rose by 14.28% to $61.3 million in 2023, then surged by 69.88% to $104.1 million in 2024, then grew by 14.94% to $119.6 million in 2025.
  • Its Accumulated Expenses stands at $119.6 million for Q3 2025, versus $107.5 million for Q2 2025 and $100.5 million for Q1 2025.